Synthesis and structure–activity relationships of a novel series of HIV-1 protease inhibitors encompassing ABT-378 (Lopinavir)
摘要:
The HIV protease inhibitor ABT-378 (Lopinavir) has a 2,6-dimethylphenoxyacetyl group in the P-2' position. Analogues in which this group is replaced with various substituted phenyl or heteroaryl groups were synthesized and the Structure-activity relationships explored. (C) 2002 Elsevier Science Ltd. All rights reserved.
The chiral tridentate spiro P‐N‐S ligands (SpiroSAP) were developed, and their iridium complexes were prepared. Introduction of a 1,3‐dithiane moiety into the ligand resulted in a highly efficient chiraliridium catalyst for asymmetrichydrogenation of β‐alkyl‐β‐ketoesters, producing chiralβ‐alkyl‐β‐hydroxyesters with excellent enantioselectivities (95–99.9 % ee) and turnover numbers of up to 355 000
A compound comprising a substituent of the formula (II) is disclosed as an HIV protease inhibitor. Intermediates for making such compounds and processes for making such intermediates are also disclosed.
the presence and absence of TMEDA, has been investigated. The results showed that metalation at the thioalkyl carbon probably occurs by direct attack of the organolithium reagent, although a transmetalationreaction cannot be excluded in some cases. It has also been found that benzylic, thio-methylic, and ring metalation occurs in ether alone, whereas mainly thio-methylic or ring metalation occurs
[EN] RETROVIRAL PROTEASE INHIBITING COMPOUNDS<br/>[FR] COMPOSES INHIBITEURS DE PROTEASES RETROVIRALES
申请人:ABBOTT LABORATORIES
公开号:WO1997021683A1
公开(公告)日:1997-06-19
(EN) Inhibitors of HIV protease are provided. When bound to HIV protease, the inhibitors are characterized by a unique three-dimensional conformation and orientation relative to the S1, S1', S2, S2', S3, and S3' subsites of the protease. Pharmaceutical compositions containing the inhibitors and methods of treating HIV infection are also provided.(FR) La présente invention concerne des inhibiteurs de protéases du VIH. Lorsqu'ils sont liés à une protéase du VIH, ces inhibiteurs sont caractérisés par une conformation et une orientation tridimensionnelles uniques par rapport aux sous-sites S1, S1', S2, S2', S3 et S3' de la protéase. L'invention concerne également des compositions pharmaceutiques contenant ces inhibiteurs et des procédés de traitement contre l'infection VIH.
Solvent-Selective Synthesis of Diaryl Disulfides and Arylthio Acetic Acids Using Thioglycolic Acid and Copper Catalysts
作者:Junghyun Chae、Kyungmi Kim、Youngjin Shin
DOI:10.1055/a-2178-1701
日期:2024.4
An efficient Cu-catalytic protocol for the synthesis of diaryl disulfides from aryl iodides using thioglycolic acid as the sulfur source has been developed. This transformation was successful only in aqueous DMSO, and when the solvent system was switched to aqueous DMF, arylthio aceticacids, the immediate C–S coupling products, were obtained. Each synthetic protocol was optimized and applied to various